SLC16A1 inhibition blocks tumor growth by increasing glucose use by oxidative cancer cells, which results in hypoxic cancer cell death due to glucose starvation (Sonveaux et al., 2008; Wang et al., 2022). This evidence concerns the gene SLC16A1 and cancer.